In last trading session, Ovid Therapeutics Inc (NASDAQ:OVID) saw 0.58 million shares changing hands with its beta currently measuring 0.26. Company’s recent per share price level of $0.62 trading at $0.05 or 8.91% at ring of the bell on the day assigns it a market valuation of $43.85M. That closing price of OVID’s stock is at a discount of -511.29% from its 52-week high price of $3.79 and is indicating a premium of 9.68% from its 52-week low price of $0.56.

For Ovid Therapeutics Inc (OVID), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.17 in the current quarter.

Ovid Therapeutics Inc (NASDAQ:OVID) trade information

Upright in the green during last session for gaining 8.91%, in the last five days OVID remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $0.62 price level, adding 7.6% to its value on the day. Ovid Therapeutics Inc’s shares saw a change of -33.87% in year-to-date performance and have moved -4.37% in past 5-day. Ovid Therapeutics Inc (NASDAQ:OVID) showed a performance of -12.16% in past 30-days.

Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 92.25% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 11. It follows that stock’s current price would drop -383.87% in reaching the projected high whereas dropping to the targeted low would mean a loss of -383.87% for stock’s current value.

Ovid Therapeutics Inc (OVID) estimates and forecasts

This year revenue growth is estimated to rise 68.02% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 187.5k for the same. And 3 analysts are in estimates of company making revenue of 100k in the next quarter. Company posted 141.56k and 148k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.87% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 37.16% while estimates for its earnings growth in next 5 years are of 17.77%.

Ovid Therapeutics Inc (NASDAQ:OVID)’s Major holders

TAKEDA PHARMACEUTICAL CO LTD is the top institutional holder at OVID for having 7.53 million shares of worth $5.79 million. And as of 2024-06-30, it was holding 10.6209 of the company’s outstanding shares.

The second largest institutional holder is RUBRIC CAPITAL MANAGEMENT LP, which was holding about 5.32 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4961 of outstanding shares, having a total worth of $4.09 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.79 shares of worth $1.11 million or 2.52% of the total outstanding shares. The later fund manager was in possession of 1.74 shares on Nov 30, 2024 , making its stake of worth around $1.08 million in the company or a holder of 2.46% of company’s stock.